DUBLIN and BARCELONA, Spain - MARCH 19, 2018 - Medtronic plc (NYSE: MDT) today announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance(TM) Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF).

Arthur J. Moss, MD, known in the cardiology field for his extensive research in diagnosing and treating long QT syndrome (LQTS), died of cancer Feb. 14 at his home in Brighton, New York. He was 86.

A new study from Cincinnati’s Children’s Hospital has found that the use of a wearable cardioverter defibrillator (WCD) is safe and effective for treating ventricular arrhythmias in pediatric patients at risk from sudden cardiac death.

Apple devices just keep getting smarter. New research presented at this year’s Heart Rhythm Society (HRS) conference in Chicago showed that when paired with an artificial intelligence-based algorithm, the watch can detect atrial fibrillation (AFib). 

MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a late-breaking clinical trial session at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions in Chicago. Data confirmed that the WATCHMAN device had a high implant success rate and was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed unsuitable for oral anticoagulation.

The Heart Rhythm Society (HRS) recently announced the late-breaking clinical trials sessions for the upcoming Heart Rhythm scientific sessions.

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced the recent publication of two documents in support of extended continuous ambulatory monitoring for arrhythmia detection.

Black people with atrial fibrillation (AF) experience vastly higher rates of serious coronary events, so it’s not surprising that a growing number of clinical studies are aggressively tackling the complex issues around the impact of race—as well as gender—on management and outcomes of the heart rhythm disorder.